Loading...
XNAS
CORT
Market cap7.96bUSD
May 16, Last price  
75.08USD
1D
2.34%
1Q
3.25%
Jan 2017
934.16%
Name

Corcept Therapeutics Inc

Chart & Performance

D1W1MN
P/E
56.98
P/S
11.79
EPS
1.32
Div Yield, %
—
Shrs. gr., 5y
-1.53%
Rev. gr., 5y
17.11%
Revenues
675m
+39.94%
0294,000482,000209,00029,000003,307,00010,357,00026,551,00050,286,00081,321,000159,201,000251,247,000306,486,000353,874,000365,978,000401,858,000482,375,000675,040,000
Net income
140m
+31.65%
-20,093,000-24,873,000-11,573,000-20,061,000-20,166,000-25,966,000-32,354,000-38,048,000-46,011,000-31,383,000-6,408,0008,140,000129,122,00075,410,00094,181,000106,011,000112,512,000101,418,000106,140,000139,733,000
CFO
198m
+55.91%
-17,234,000-23,238,000-10,964,000-18,362,000-17,968,000-22,285,000-27,400,000-36,020,000-37,058,000-27,376,0003,130,00018,391,00060,935,000115,665,000136,117,000151,970,000167,892,000120,323,000127,039,000198,067,000
Earnings
Jul 28, 2025

Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
URL
https://www.corcept.com/
IPO date
Apr 15, 2004
Employees
299
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
675,040
39.94%
482,375
20.04%
401,858
9.80%
Cost of revenue
257,769
190,834
136,376
Unusual Expense (Income)
NOPBT
417,271
291,541
265,482
NOPBT Margin
61.81%
60.44%
66.06%
Operating Taxes
20,284
18,417
14,773
Tax Rate
4.86%
6.32%
5.56%
NOPAT
396,987
273,124
250,709
Net income
139,733
31.65%
106,140
4.66%
101,418
-9.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(15,664)
(139,617)
(17,284)
BB yield
0.27%
3.85%
0.73%
Debt
Debt current
829
302
1,143
Long-term debt
13,043
151
2,286
Deferred revenue
Other long-term liabilities
14,084
10,307
7,954
Net debt
(369,462)
(424,944)
(438,137)
Cash flow
Cash from operating activities
198,067
127,039
120,323
CAPEX
(2,172)
(139)
(413)
Cash from investing activities
(177,604)
90,906
(114,327)
Cash from financing activities
(28,349)
(148,723)
(17,284)
FCF
389,289
273,952
299,588
Balance
Cash
383,334
368,221
436,619
Long term investments
57,176
4,947
Excess cash
349,582
401,278
421,473
Stockholders' equity
543,654
403,268
295,648
Invested Capital
351,027
116,036
207,248
ROIC
169.99%
168.97%
116.82%
ROCE
59.56%
56.36%
52.79%
EV
Common stock shares outstanding
113,480
111,742
115,966
Price
50.39
55.14%
32.48
59.92%
20.31
2.58%
Market cap
5,718,257
57.55%
3,629,380
54.10%
2,355,269
-5.57%
EV
5,348,795
3,204,436
1,917,132
EBITDA
418,607
293,903
268,451
EV/EBITDA
12.78
10.90
7.14
Interest
3,557
Interest/NOPBT
1.34%